The benefit that matters to you may be sleeping through the night or getting through the workday without disruptive hot flashes. Those are specific goals. A useful hormone-therapy conversation connects them to your medical history, the proposed product, and a plan to check how things are going.
Neither a frightening headline nor a reassuring advertisement can make that assessment for you. Current guidance leaves room for individualized treatment while retaining important safety questions.
A label change should prompt a closer reading of the current product information, not the assumption that risk has disappeared.
Name the benefit you hope to notice
Hormone therapy can relieve menopausal symptoms, including hot flashes and night sweats; local treatments may address vaginal symptoms. Ask what improvement is reasonable to look for, when to review it, and what to do if it does not happen.
Treatment should not be sold as a universal way to prevent aging or cardiovascular disease. Our introductory guide helps keep the conversation tied to a symptom and a clinical purpose.
Reading behind this section: ACOG: hormone therapy for menopause
Bring the history that changes the decision
Age and time since menopause are part of the assessment, alongside the type of treatment and your medical history. Prior blood clots, stroke, heart attack, some cancers, liver disease, or unexplained bleeding can substantially change what is appropriate.
Tell the clinician about medicines and relevant family history too. This article cannot decide whether hormones are suitable for you. Use the conversation prompts to prepare questions rather than treating a general risk list as a personal clearance.
Reading behind this section: ACOG: hormone therapy for menopause · The Menopause Society: hormone therapy
What changed in 2026?
On February 12, 2026, FDA announced approved labeling changes for an initial group of six menopausal hormone therapy products, following its earlier request to manufacturers. Certain cardiovascular, breast-cancer, and probable-dementia statements were removed from those products’ boxed warnings.
This was a product-specific labeling action. It does not mean every hormone product has identical updated labeling or that those outcomes are impossible. Ask the prescriber or pharmacist to review the current label for the exact prescription, including remaining warnings and contraindications.
Reading behind this section: FDA: February 2026 hormone-therapy labeling update · FDA: November 2025 labeling request
Keep the conversation open
Agree on a follow-up plan that revisits symptom relief, unwanted effects, new health information, and whether the treatment still fits. Ask whom to contact about bleeding or other concerning changes, and use emergency services for severe acute symptoms.
Different routes and formulations should not be treated as one interchangeable intervention. Read local versus systemic estrogen and the compounding explanation before drawing conclusions from another person’s experience or a broad provider claim.
Reading behind this section: ACOG: hormone therapy for menopause · ACOG: compounded bioidentical hormone therapy
Our source notes
- ACOG: hormone therapy for menopause
Clinical patient guidance; individual history and the actual product label still govern treatment decisions.
- The Menopause Society: hormone therapy
Specialty-society patient guidance; benefits and risks require individual assessment.
- FDA: February 2026 hormone-therapy labeling update
Announcement of approved changes to six products; not proof that every warning on every product has disappeared.
- FDA: November 2025 labeling request
Context for requested changes. Requests and approved product-specific labels are different stages.
- ACOG: compounded bioidentical hormone therapy
Clinical consensus distinguishes FDA-approved bioidentical medicines from compounded preparations.
